- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- DAY301
- Drug
- Lead sponsor
- Day One Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Sarasota, Florida • Avon, Indiana + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2305–2328
of 11,389
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis B Infection, Malignant Solid Neoplasm
- Interventions
- Best Practice, Entecavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate
- Other · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 192
- States / cities
- Fort Smith, Arkansas • Anaheim, California • Antioch, California + 140 more
- Conditions
- In-hospital Mortality, Non-COVID Deaths, Surge
- Interventions
- COVID-19 Surge
- Other
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30,000,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Vitiligo
- Interventions
- TEV-53408
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Hot Springs, Arkansas • Fremont, California + 10 more
- Conditions
- Hypercholesterolemia
- Interventions
- PF-05335810 Dose A, PF-05335810 Dose B, Placebo, PF-04950615 Dose A, PF-05335810 Dose C, PF-04950615, PF-05335810 Dose D, PF-05335810 Dose E
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Miami, Florida • South Miami, Florida + 4 more
- Conditions
- Healthy
- Interventions
- PF-07328948, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Crohn Disease
- Interventions
- Etrolizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 62
- States / cities
- Arcadia, California • La Jolla, California • Long Beach, California + 53 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Glioblastoma Multiforme, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Renal Cell Carcinoma
- Interventions
- DSP-7888 Dosing Emulsion
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Atlanta, Georgia • Lafayette, Indiana + 5 more
- Conditions
- Healthy Volunteer
- Interventions
- Subcutaneous RB006 0.5 mg/kg, Subcutaneous RB006 1.0 mg/kg, Subcutaneous RB006 3.0 mg/kg, Subcutaneous RB006 2.0 mg, Placebo
- Drug
- Lead sponsor
- Regado Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Stroke, Parkinson Disease, Lower Limb Amputation Above Knee (Injury), Lower Limb Amputation Below Knee (Injury)
- Interventions
- Database Entry
- Other
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- Up to 99 Years
- Enrollment
- 250 participants
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Recurrent Genital Herpes Simplex Type 2
- Interventions
- ABI-1179, ABI-1179 Placebo
- Drug
- Lead sponsor
- Assembly Biosciences
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Kansas City, Missouri • Rochester, New York • Seattle, Washington
- Conditions
- Androgenetic Alopecia
- Interventions
- KX0826, Placebo
- Drug · Other
- Lead sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Industry
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Maraviroc
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Orange, California • Wilmington, Delaware + 10 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Vandetanib, Cyclophosphamide, Methotrexate
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Safety and Tolerability
- Interventions
- Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
- Drug
- Lead sponsor
- MerLion Pharmaceuticals GmbH
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Heart Failure
- Interventions
- Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 22
- States / cities
- Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
- Conditions
- Low Back Pain
- Interventions
- Intracept Procedure
- Procedure
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Farmington, Utah • Salt Lake City, Utah • South Jordan, Utah
- Conditions
- Stargardt's Macular Dystrophy
- Interventions
- MA09-hRPE
- Biological
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania
- Conditions
- Cancer-related Cognitive Dysfunction, Primary Brain Neoplasm
- Interventions
- Aerobic Exercise, Behavioral Intervention, Follow-Up, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Resistance Training
- Other · Behavioral · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 15 Years to 39 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Houston, Texas
- Conditions
- Inflammatory Bowel Diseases, Crohns Disease, Ulcerative Colitis, Colitis
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Ornithine Transcarbamylase (OTC) Deficiency
- Interventions
- scAAV8OTC, Reactive Corticosteroid Taper Regimen, Prophylactic Corticosteroid Taper Regimen
- Genetic · Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Advanced Cancer
- Interventions
- BMS-986406, Nivolumab, Carboplatin, Pemetrexed, Paclitaxel
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 5 more
- Conditions
- Breast Augmentation
- Interventions
- Exparel Injectable Product, Bupivacaine Hydrochloride
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Bellaire, Texas
- Conditions
- Chronic Traumatic Brain Injury
- Interventions
- Anti-inflammatory Diet, N-acetyl Cysteine, Neuro Emotive Technique
- Other · Dietary Supplement · Behavioral
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Villanova, Pennsylvania